Projets par an
Introduction: Lupus anticoagulant (LA) testing requires normal pooled plasma (NPP) in performing mixing studies and can be used for normalized ratios of clotting times (CTs). The aims were to demonstrate whether significant differences in clotting times between two batches of a same commercial NPP (CRYOcheck™) directly affect NPP-based cut-off values. Methods: Diluted Russell Viper venom time (DRVVT) and activated partial thromboplastin time (aPTT) were used for LA testing. Screening, mixing and confirm tests were performed with Stago® instruments and reagents. Two batches of commercial NPP (A1291 and A1301 from CRYOcheck™; frozen) were compared in the determination of cut-off values. Cut-off values were defined as 99th percentile values of 60 healthy donors and compared with Mann–Whitney U test. Results: Cut-off values obtained with the two NPP batches were significantly different for DRVVT (screen normalized ratio: 1.09 vs. 1.24, screen mix: 41.9 s vs. 38.9 s; index of circulating anticoagulant: 5.0 vs. 8.4; all had p-value <.001). On the contrary, no significant differences were observed for aPTT (screen normalized ratio: 1.32 vs. 1.34; p-value =.4068, screen mix: 37.8 s vs. 38.1 s; p-value =.1153) except for index of circulating anticoagulant: 9.6 versus 10.4 (p-value <.05). Conclusion: This study demonstrates that differences between two commercial NPP batches produced by a same manufacturer influenced LA cut-off values used for mixing studies and normalized ratios. Adequate cut-off setting, taking into account NPP CTs, is important to provide accurate conclusion about the presence or absence of a LA and avoid potential clinical impact.
|Pages (de - à)||126-136|
|Nombre de pages||11|
|journal||International Journal of Laboratory Hematology|
|Numéro de publication||1|
|Date de mise en ligne précoce||12 oct. 2022|
|Etat de la publication||Publié - févr. 2023|
Empreinte digitaleExaminer les sujets de recherche de « Variability among commercial batches of normal pooled plasma in lupus anticoagulant testing ». Ensemble, ils forment une empreinte digitale unique.
- 2 Actif
Clinical Pharmacology Research Group
Douxfils, J., Dogne, J., Musuamba Tshinanu, F., MASEREEL, B., Wieers, G., Haguet, H., RONVAUX, L., Donis, N., Morimont, L., Evrard, J., Siriez, R., Gillot, C., FAVRESSE, J., BOUVY, C., Djokoto, H., Didembourg, M., David, C., Melchionda, S., Maloteau, V., Boucher, A., Devel, P., Modaffari, E., Vandeputte, M., De Messemaeker, A., Decarpentrie, J., Vassart, J. & De Groote, A.
1/04/22 → …
Projet: Axe de recherche
The BIOCOAG project : Biological assessment of the control of anticoagulation
Douxfils, J., MULLIER, F., Dogne, J., Siriez, R. & Evrard, J.
1/09/11 → …